
    
      OBJECTIVES:

      Primary: To assess the pharmacokinetics of VSLI administered intravenously to patients with
      malignant melanoma and hepatic dysfunction secondary to metastases.

      Secondary: To assess the safety and antitumor activity of VSLI in this population.
    
  